CCRB Logo

Trial History Detail on 2009-11-19

CUHK_CCT00051

2005-09-09

Retrospective

Takeda Chemical Industries, LTD

Department of Medicine & Therapeutics, The Chinese University of Hong Kong

N/A

Leata Yeung

Department of Medicine & Therapeutics, The Chinese University of Hong Kong

leata@chuk.edu.hk

Prof. John E. Sanderson

John.Sanderson@uhns.nhs.uk

Professor of Cardiology, Keele University Medical School

The effect of angiotensin receptor blockade alone or in combination with spironolactone on the process of ventricular remodeling in chronic heart failure.

Yes

2001-07-03

Heart and Blood Vessel Diseases

Drug

Heart Failure Patients

one year

Candesartan + Spirolactone verus Candesartan + Placebo

Inclusion criteria *Typical features of congestive heart failure. *LVEF < 40%.

Exclusion criteria *Patients with renal failure, serum creatinine > 200 mmol/ltr. *Other major serious medical conditions such as malignancy, liver failure, uncontrolled diabetes. Gender and age will be balanced in the two randomized groups.

Randomized

Placebo

Double-blind

Parallel

2001-10-08

50

Complete

We sought to determine the beneficial effect of candesartan alone or in combination with spironolactone on left ventricular remodelling

N/A

No

2009-12-28


Yes

Type Access Document Published On  
No documents yet.
  • Page 1 of 1.